RxDoctor Payments Data

Shweta Adya, MD

Internal Medicine · Irving, TXNPI 1447253687

Payments from drug & device makers

$4,669in general payments, 2019–2025

Across 306 payments — averaging $15.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$904
  • Novo Nordisk$880
  • GSK$478
  • Lilly USA, LLC$447
  • AbbVie$437
  • Boehringer Ingelheim$252
  • plus $1K from 26 others

What the payments were for

  • Food & beverage$4,662100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,669 in reported general payments places this provider in the 85th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$37,867
Medicare patients
68
Services billed
723

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide96$119,295
JardianceEmpagliflozin48$83,428
JanuviaSitagliptin Phosphate46$63,634
FarxigaDapagliflozin Propanediol39$49,069
EliquisApixaban24$39,422
Lidocaine110$37,725
RybelsusSemaglutide17$34,558
Dexlansoprazole DrDexlansoprazole51$23,799
ProliaDenosumab11$19,177
MounjaroTirzepatide18$18,872
Alcohol PadsAlcohol Antiseptic Pads69$17,583
Breo ElliptaFluticasone/Vilanterol24$14,167
Easy Comfort Pen NeedlePen Needle, Diabetic44$12,710
Metformin Er GastricMetformin Hcl15$8,788
Lantus SolostarInsulin Glargine,hum.Rec.Anlog64$6,937

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$880$153,853113 claims
Boehringer IngelheimJardiance$252$83,42848 claims
MerckJanuvia$235$63,63446 claims
AstraZenecaFarxiga$904$49,06939 claims
PfizerEliquis$162$39,42224 claims
AmgenProlia$15$19,17711 claims
Lilly USA, LLCMounjaro$447$18,87218 claims
GSKBreo Ellipta$478$14,16724 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Irving

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →